April 25, 2018 12:48 AM ET


Company Overview of Io Therapeutics, Inc.

Company Overview

Io Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapeutic compounds for cancer, and neurodegenerative and autoimmune diseases. The company offers retinoid and rexinoid molecule drugs for prostate, non small cell lung, breast, and pancreatic cancers; neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases, traumatic brain injury, and other diseases; and autoimmune diseases, including multiple sclerosis and others. Io Therapeutics, Inc. was founded in 2010 and is based in Santa Ana, California.

1805 East Garry Avenue

Suite 110

Santa Ana, CA 92705-5851

United States

Founded in 2010



Key Executives for Io Therapeutics, Inc.

Co-Founder, Executive Chairman and Chief Executive Officer
Co-Founder, President, Chief Scientific Officer and Director
Age: 68
Co-Founder, Director and Member of Scientific Advisory Board
Vice President of Business Development
Vice President of Regulatory Affairs
Compensation as of Fiscal Year 2017.

Io Therapeutics, Inc. Key Developments

Io Therapeutics, Inc. Reports Data Demonstrating of the Candidate Treatment for Multiple Sclerosis, IRX4204, Promotes Repair of Damaged Myelin

Io Therapeutics, Inc. has reported data demonstrating that the company's experimental rexinoid nuclear receptor (RXR) agonist compound, IRX4204, promotes repair of myelin in a mouse model of multiple sclerosis (MS). Myelin is a tissue in the brain and spinal cord which is damaged by an autoimmune process in MS, resulting in progressive disability and death. Finding new treatments, which promote repair of myelin is a major focus of current MS research. The company's data were presented at the 32nd Congress of The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), currently being held in London, England. The reported studies were supported by funding from the US National Multiple Sclerosis Society's Fast Forward Program. In MS, autoimmune processes damage the myelin sheath surrounding nerve fibers, resulting in dysfunction of signal transmission in the brain and spinal cord. Myelin damage contributes to physical disability in MS patients. Many currently available treatments for MS target the autoimmune processes, but to date, none have been conclusively demonstrated to promote repair of damaged myelin in MS patients. The company has previously reported that IRX4204 has beneficial effects on autoimmunity, and protects against loss of neurons, in animal models of MS. The current data, showing that IRX4204 promotes repair of damaged myelin in an animal model of MS, demonstrates a third critically important mechanism of action of the drug as a promising potential treatment for MS.

Similar Private Companies By Industry

Company Name Region
Praetego, Inc. United States
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Io Therapeutics, Inc., please visit www.io-therapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.